“As of November 2020, late-stage clinical stud

“As of November 2020, late-stage clinical studies for numerous repurposed antibody therapeutics (Table 1) were recruiting patients, and emergency use authorizations (EUAs) had been requested or granted for 3, anti-IL-6 receptor levilimab, anti-CD6 itolizumab, and anti-C-C chemokine receptor type 5 (CCR5) leronlimab.“

Looks like they did request EUA for CD10 ? Although they said they didn’t? Maybe this is accurate but I found it interesting.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833761/

I find it comical and also disgusting at the same time how BP get EUA for all their drugs while Leronlimab sits on the shelves. What a joke.

Daniel Rizzo
Federal Whistleblower / Special Operations Tactical Unit
USAF: Phoenix Raven #2143
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565


Founder & CEO of FireGate Bioscience
USPTO: Lead Inventor of the HIV Cure & AI Federal Oversight Program

⸻

Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com